Status:
COMPLETED
Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia
Lead Sponsor:
Assiut University
Conditions:
Covid19 Related Anosmia and Aguesia
Eligibility:
All Genders
20-50 years
Phase:
PHASE3
Brief Summary
The loss of smell and taste is a prominent symptom of COVID-19. Studies found that patterns of smell loss due to Covid-19 infection differ from that of other respiratory viruses being much more profou...
Detailed Description
Initial descriptions of the COVID-19 pandemic have focused on its acute severe manifestations. After several months, data have emerged about the mild disease and Post-COVID syndrome. The diminished se...
Eligibility Criteria
Inclusion
- A random sample of at least 250 adults with sudden hyposmia/anosmia and/or hypoageusia/ageusia during COVID-19 pandemics and experienced persistent olfactory and/or gustatory manifestations after recovery from other acute viral manifestations.
- compliance for drug intervention (group 1) or olfactory training (group 2) for at least 8 weeks.
Exclusion
- Prior neurologic, medical or psychiatric disease.
- Other known infection at onset
- Nasal congestion
- Nasal polyps
- Surgery or head trauma or radiation for head and neck cancers as may result in injury to the nerves that control smell
- Exposure to toxic chemicals (such as pesticides and solvents)
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04830943
Start Date
August 1 2020
End Date
October 30 2022
Last Update
January 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospitals, Faculty of Medicine
Asyut, Egypt, 71516